Durvalumab and Tremelimumab in Resectable HCC

Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of care highlighting the role of immune checkpoint inhibition in advanced HCC. In addition, the combination of Tremelimumab and Durvalumab has demonstrated efficacy in advanced HCC; the HIMALAYA trial has now completed accrual in treatment naïve patients with advanced H

Trial Details

NCT ID
NCT05440864
Phase
PHASE2
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Tremelimumab
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Milan, Italy|45.46427,9.18951
  • Pamplona, Spain|42.81687,-1.64323

Key Eligibility Criteria

  • For inclusion in the study, patients should fulfil the following criteria at time of study enrolment or when indicated:
  • Patient must be capable of providing written informed consent.
  • Age \>18 years at time of study entry
  • Histologically proven resectable HCC (early and intermediate stage HCC)\*

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →